A decade ago I wrote an article in the journal Nature Biotechnology about the rise of a new gene editing technology called zinc finger nucleases (ZNF). It was one of those “drumbeat” discoveries: at the time, my sense was it would revolutionize how we deliver genes to cells and tissues, and profoundly change the way […]
Guest Post by Chris Scott–The Great CRISPR Controversy: What’s Next? Read More »
The Juan Carlos Izpisua Belmonte group published a Cell paper today on using gene editing to reverse mutations associated with human mitochondrial disease. The paper is Reddy, et al. and is entitled, “Selective Elimination of Mitochondrial Mutations in the Germline by Genome Editing”. The authors report success using TALEN-based gene editing or mitochondrial-direct restriction enzyme (mito-ApaLI)
Juan Carlos Izpisua Belmonte Cell Paper on Gene Editing for Mitochondrial Disease Read More »
Practical Plan for Managing Human Germline Genetic Modification CRISPR-Cas9 gene editing technology is a game changer on many levels both inside and soon outside the lab. There is a growing sense of urgency amongst biomedical scientists to take a proactive approach to current and future use of CRISPR technology in human germ cells and embryos.
With the House of Lords vote yesterday, the UK officially became the only country in the world to have legalized human genetic modification via 3-Person IVF. The point of this “mitochondrial transfer” or “3-person IVF” technology is not directly to genetically modify humans specifically, but it still will lead to that result in any case.
UK OKs 3-Person IVF: Perspectives Read More »
It’s been somewhat of a helter-skelter time for the new technology often referred to as 3-person IVF or mitochondrial transfer as the UK considers whether to legalize this experimental technology for use in humans. I believe that this technology is not ready now for use in humans and for more background on why as well
Myths about 3-person IVF mitochondrial transfer Read More »
What’s Cambrian Genomics? With rapid advances in genomics, gene editing, and methods to reproduce life in the lab such as cloning, today creating genetically modified organisms (GMOs) has never been easier. While there have been of course loads of discussions of GMOs in the past, we are entering a new era of what one might
Austen Heinz of Cambrian Genomics Interview: GMO creatures & people Read More »
Every year I do a list of top predictions for the coming year for the stem cell and regenerative medicine field. For example, you can see past top 10 predictions lists for 2013 and 2014. What’s in store for 2015 from the stem cell crystal ball? There is so much going on that for this
Stem Cell Predictions for 2015 Read More »
The following is a response to my Open Letter to the UK Parliament on mitochondrial transfer/3-parent technology from Drs. Peter Braude and Robin Lovell-Badge. Dear Professor Knoepfler, We read your open letter to the UK Parliament and the Science and Technology Committee with interest and concern. We are two scientists, like you, with particular interests
Dear UK Parliament and Science and Technology Committee, I am writing to you about your deliberations on “mitochondrial donation” (also known as 3-parent technology) intended for the purpose of preventing heritable mitochondrial disorders. I am concerned about the Department of Health’s recent draft regulations that would allow 3-parent experiments to go forward and the possibility that the UK
Open letter to UK Parliament: avoid historic mistake on rushing 3-parent technology Read More »
An FDA committee began a meeting yesterday that continues today to consider permitting new assisted reproduction-based “3-parent” technology that could address mitochondrial disorders, a serious human health problem. The technology also raises complex health issues of its own and invokes ethical questions. The goal of the FDA meeting is articulated this way: “the committee will
Why the FDA should not green-light 3-parent reproduction Read More »